Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 7/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.61 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.61 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.61 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.54 |
| ▸ | PRCP | P42785 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | BCR | P11274 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2706696 | 1.00 | CYP3A4 (0.61) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL206035 | 1.00 | CYP3A4 (0.61) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL19339693 | 1.00 | CYP3A4 (0.61) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL205542 | 0.95 | CYP3A4 (0.67) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL13070993 | 0.95 | CYP3A4 (0.67) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL205543 | 0.95 | CYP3A4 (0.67) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL15993131 | 0.95 | CYP3A4 (0.67) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL19318807 | 0.94 | CYP3A4 (0.53) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL19318708 | 0.93 | CYP3A4 (0.58) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL19323321 | 0.93 | CYP3A4 (0.58) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170253614-A1 | HEPATITIS C VIRUS INHIBITORS AND USES THEREOF IN PREPARATION OF DRUGS | CHANGZHOU YINSHENG PHARMACEUTICAL CO., LTD. (CN) | 2017-09-07 | — | — | US | disclosed |
| US-9511056-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2016-12-06 | — | — | US | disclosed |
| EP-3002281-A1 | ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2016-04-06 | — | — | EP | disclosed |
| US-20140249074-A1 | ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC (US) | 2014-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170253614-A1 | HEPATITIS C VIRUS INHIBITORS AND USES THEREOF IN PREPARATION OF DRUGS | HAVCR2, HCCS, LIPC | CYP3A4 177/4885CYP2C9 519/4885KCNH2 4324/4885 |
| US-20140249074-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | CYP3A4 1770/4885CYP2C9 3296/4885KCNH2 4228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.